AMGN•benzinga•
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 6, 2025 by benzinga